HOME >> BIOLOGY >> NEWS
Latest data shows MabThera provides significant, sustained relief from symptoms of RA

Barcelona, Spain. New data presented at the EULAR meeting (European League Against Rheumatism) demonstrate that MabThera's (rituximab) effectiveness in relieving patients of the distressing symptoms of rheumatoid arthritis (RA) is sustained or further improved with subsequent courses of treatment, as is the number of patients achieving remission1. Importantly, the safety profile of MabThera remained unchanged in patients who had received as many as seven courses of treatment at 6-12 month intervals.

Commenting on the findings, Professor Keystone, Rheumatology Department at the University of Toronto, Canada, said: "As physicians gain experience with MabThera and the long-term efficacy and safety data are collected, we are able to make treatment decisions with confidence for the ultimate benefit of our patients."

Results following subsequent courses of therapy

A total of 1053 RA patients was treated with MabThera with almost 70% of patients followed up for more than two years and 11% for more than three years. The study was conducted in patients who had an inadequate response to treatment with either tumour necrosis factor (TNF) inhibitors or disease-modifying anti-rheumatic drugs (DMARDs), both of which are commonly used classes of RA drugs. All study patients received multiple courses of MabThera (2 x1000mg infusion, 2 weeks apart) based on disease activity.

The data showed that after three courses of MabThera in patients who had an inadequate response to TNF inhibitors:

  • The number of patients achieving the hard-to-reach goal of a 70% improvement in disease signs and symptoms (ACR70 response2) almost tripled from 11% to 25%

  • The number of patients achieving remission improved from 6% to 12%

Equally, in patients with an inadequate response or intolerance to DMARDs, the remission rate increased almost threefold from 5% to 14% confirming the benefit of providing subsequen
'"/>

Contact: Lynn Huynh
lynn_huynh@uk.cohnwolfe.com
44-207-331-5332
Cohn & Wolfe, London
13-Jun-2007


Page: 1 2

Related biology news :

1. Latest strategies for moving research toward a cure for diabetes explored at global scientific forum
2. Latest plant health research to be presented in San Diego
3. Latest advances in DNA sequencing highlighted at DOE Joint Genome Institute User Meeting
4. Latest buzz: Marijuana may slow progression of Alzheimers disease
5. Latest enhancements to the free Access Grid Toolkit are now available for download
6. Slow-frozen people? Latest research supports possibility of cryopreservation
7. Latest plant disease research to be presented in Quebec City
8. Latest study: Scientists say no evidence exists that therapod dinosaurs evolved into birds
9. Latest gene therapy research to be presented in St. Louis, June 1-5, 2005
10. Latest census finds more American pika populations disappear as climate warms
11. Latest buzz in research: Intoxicated honey bees may clue scientists into drunken human behavior

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/4/2019)... ... 02, 2019 , ... Stay on top of current hot topics through free ... to all webinars is free, so be sure to register today to save your ... http://www.xtalks.com to see our upcoming webinars: , CLINICAL OPERATIONS , August 27 – ...
(Date:8/1/2019)... ... July 31, 2019 , ... Molecular ... launch of the next generation of its FLIPR® Penta High-Throughput Cellular Screening System. ... FLIPR® platform for monitoring of G-protein-coupled receptors (GPCRs) and ion channels, offering a ...
(Date:7/24/2019)... ... July 24, 2019 , ... NDA Partners Chairman Carl ... with more than 20 years of experience working in scientific research and FDA-regulated ... as an Expert Consultant. , Dr. Hartzfeld has experience in all aspects of ...
Breaking Biology News(10 mins):
(Date:6/11/2019)... ... June 10, 2019 , ... ... add 80 of its scientific journals to DeepDyve’s rental service for peer-reviewed journals. ... continually expanding library of more than 20 million articles, sourced from more than ...
(Date:6/11/2019)... DURHAM, N.C. (PRWEB) , ... June 11, 2019 ... ... how extracellular vesicles derived from human mesenchymal stem cells (MSC-EV) are able to ... and cloning ability. In a test on mice, MSC-EVs also increased the cells’ ...
(Date:5/31/2019)... ... May 29, 2019 , ... ... from the USPTO providing proprietary interest to our methodology, processes, and diagnostic ... DIAGNOSIS AND TREATMENT… extends Somnology’s IP rights including our proprietary sleep scoring ...
(Date:5/31/2019)... ... May 30, 2019 , ... A study released today ... system for the sustained release of human placental stem cell (HPSC)-derived conditioned medium ... to deliver CM into the injured kidney, where it helped restore function and ...
Breaking Biology Technology:
Cached News: